BRAF and MEK inhibition beyond dabrafenib–trametinib in advanced thyroid cancer: a real-world case series
This case series highlights the potential benefits and challenges of targeted therapies in advanced thyroid cancer. While BRAF and MEK inhibitors offer new treatment options, toxicity management and the development of resistance remain significant hurdles. The limited FDA-approved options for BRAF V600E-positive thyroid cancer compared to melanoma underscore the need for further research to optimize and expand treatment strategies.
Authors
- Mor Miodovnik (ORCID: https://orcid.org/0000-0001-8027-4631)
- Elena Izkhakov (ORCID: https://orcid.org/0000-0002-4742-878X)
- Inbar Finkel
- Eyal Robenshtok (ORCID: https://orcid.org/0000-0002-6268-4212)
- Orit Gutfeld
- Oded Cohen (ORCID: https://orcid.org/0000-0002-8666-3571)
- Anton Warshavsky (ORCID: https://orcid.org/0000-0001-8163-5291)
- Tzahi Yamin (ORCID: https://orcid.org/0000-0002-6252-3646)
- Yasmin Leshem (ORCID: https://orcid.org/0000-0002-8264-1308)
- Nidal Muhanna
- Roman Meirovitz
Institutions
- Tel Aviv Sourasky Medical Center (IL)
- Rabin Medical Center (IL)
- Assuta Medical Center (IL)
- Hypertension Institute (US)
- National Medical Research Center of Dentistry and Maxillofacial Surgery (RU)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fendo.2026.1694805
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00